HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Cathepsin B

A lysosomal cysteine proteinase with a specificity similar to that of PAPAIN. The enzyme is present in a variety of tissues and is important in many physiological and pathological processes. In pathology, cathepsin B has been found to be involved in DEMYELINATION; EMPHYSEMA; RHEUMATOID ARTHRITIS, and NEOPLASM INVASIVENESS.
Also Known As:
Cathepsin B-Like Proteinase; Cathepsin B1; Cathepsin B Like Proteinase; Proteinase, Cathepsin B-Like
Networked: 1228 relevant articles (16 outcomes, 174 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Rao, Jasti S: 24 articles (05/2014 - 12/2002)
2. Sloane, Bonnie F: 23 articles (03/2015 - 07/2002)
3. Dinh, Dzung H: 16 articles (03/2013 - 12/2002)
4. Gondi, Christopher S: 14 articles (10/2013 - 06/2004)
5. Gujrati, Meena: 13 articles (03/2013 - 12/2002)
6. Sameni, Mansoureh: 12 articles (03/2015 - 02/2002)
7. Kos, Janko: 11 articles (08/2015 - 01/2002)
8. Sloane, B F: 11 articles (09/2014 - 01/2000)
9. Reinheckel, Thomas: 10 articles (03/2015 - 03/2006)
10. Kos, J: 10 articles (07/2008 - 01/2000)

Related Diseases

1. Neoplasms (Cancer)
2. Carcinoma (Carcinomatosis)
3. Pancreatitis
4. Wounds and Injuries (Trauma)
5. Edema
12/01/1992 - "CS administration (15 milligrams, twice a day) for 14 days caused a significant increase in serum amylase levels, pancreatic amylase and cathepsin B content and mild acinar cell vacuolization and interstitial edema. "
04/01/2007 - "The features of cell death, including 7-AAD staining, the presence of cellular edema, and early membrane damage resulting in lactate dehydrogenase (LDH) release, indicated that it was more likely to be necrosis than apoptosis, and was effectively blocked with the cathepsin B-specific inhibitor CA-074-Me. "
04/01/1990 - "Hemorrhagic shock did not alter the degree of hyperamylasemia, pancreatic edema, cathepsin B subcellular redistribution, or in vitro LDH leakage that characterize this model of pancreatitis. "
05/01/1992 - "After PBDO with ischemia, we observed hyperamylasemia, pancreatic edema, congestion of amylase and lysosomal enzyme cathepsin B as well as impaired output of amylase and cathepsin B into the pancreatic juice and a redistribution of lysosomal enzyme from the lysosomal fraction to the zymogen fraction. "
04/01/1993 - "Twelve hours after PBDO with IDH plus ISCH, we observed hyperamylasemia (23 +/- 3 units per milliliter) (p < 0.01); moderate pancreatic histologic changes; pancreatic edema (water content--81 +/- 2 percent) (p < 0.02), as well as the impaired amylase (2,889 +/- 328 units per kilogram per hour) (p < 0.01) and cathepsin B output (7 +/- 3 units per kilogram per hour) (p < 0.01) into the pancreatic juice of rats stimulated by caerulein (control group--serum amylase levels, 6 +/- 1 units per milliliter; pancreatic water content, 74 +/- 1 percent. "

Related Drugs and Biologics

1. Caerulein (Ceruletide)
2. Protease Inhibitors (Protease Inhibitor)
3. Malate Dehydrogenase (Dehydrogenase, Malate)
4. Amylases
5. Laminin (Merosin)
6. Cystatin C
7. Amyloid Precursor Protein Secretases (beta-Secretase)
8. Galactosamine
9. Amyloid (Amyloid Fibrils)
10. Leukocyte Elastase (Neutrophil Elastase)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)
3. Therapeutics
4. Ligation
5. Intraperitoneal Injections